ESR1 and breast cancer: Molecular subtyping of BC revealed that 66% were luminal A (ER+ and/or PR+ with HER2−), 19% were luminal B (ER+ and/or PR+ with HER2+), 6% were HER2+ positive only (ER and PR both negative), and 9% were triple-negative BC (TNBC).